Results 131 to 140 of about 137,068 (205)

Primary, Secondary and Exploratory Endpoints in Phase 2 and 3 Clinical Trials with Novel Therapies in MASH Cirrhosis: A Systematic Review. [PDF]

J Clin Med
Żurakowski G, Wiela-Hojeńska A, Petryszyn P.   +2 more
europepmc   +1 more source

Targeting SPHK1 by 8-HETrE attenuates MASH-Driven fibrosis via restoration of hepatic stellate cell mitochondrial dynamics. [PDF]

Cell Biol Toxicol
Chen S, Li J, Xu K, Wen J, Zhang F, Zhuge Y, Wang L, Yi Y, Zhang H, Zhang W.   +9 more
europepmc   +1 more source

Correction: Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model <i>in vivo</i>. [PDF]

Front Pharmacol
Li H, Xi Y, Xin X, Feng Q, Hu Y.
europepmc   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. [PDF]

Diabetes Obes Metab
Tsakiridis EE, Steinberg GR.
europepmc   +1 more source

Beyond the Green Light: Evaluating the Uncertainties of Resmetirom for Non-Cirrhotic Nonalcoholic Steatohepatitis Treatment. [PDF]

Health Sci Rep
Sajid HMM, Rahman F, Mahmoud A.
europepmc   +1 more source

New Treatment Options for MASLD Patients with Type 2 Diabetes. [PDF]

Life (Basel)
Mega A, A.I.G.O. (Italian Association of Hospital Gastroenterologists) and C.L.E.O. (Italian Association of Hospital Hepatologists), Turri C, Marzi L, Dauriz M, Sacco R, Floreani A, Stasi C.   +7 more
europepmc   +1 more source

Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances. [PDF]

Front Endocrinol (Lausanne)
Zhu B.
europepmc   +1 more source

Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints. [PDF]

Heart Fail Rev
Mahmod M, Dennis A, Lian J, Langford C, Rahimi K, Wamil M.   +5 more
europepmc   +1 more source

Real-world predictors of progression to type 2 diabetes among adults with prediabetes. [PDF]

Diabetes Obes Metab
Dunn T, Doshi R, Divino V, Chen J, Radin M, Tian D, Xie L, Solis-Herrera C.   +7 more
europepmc   +1 more source

Correction. [PDF]

Cell Mol Gastroenterol Hepatol
europepmc   +1 more source